| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 36.71 | -0.27 (-0.73%) | 27.28 - 38.74 | 147.7 thousand |
Market data as of 4:04PM 06/18/13. Quotes are delayed by at least 15 min.
| Open | 36.29 |
|---|---|
| Previous Close | 36.98 |
| Day's Range | 36.29 - 36.80 |
| Market Cap | 6.2B |
| Avg Volume (10 Day) | 160.2K |
| Price/Earnings (Trailing 12 Mo.) | -- |
| Earnings Per Share (Trailing 12 Mo.) | 0 |
| Dividend Yield | 0.2476 (0.67%) |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Fail |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Pass |
| Increased shareholder value? | Pass |
| Consistently increased owner earnings? | Fail |
| Sells at 25% discount to intrinsic value? | Fail |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Pass |
|---|---|
| Room to increase dividends? | Fail |
| Increased earnings over time? | Fail |
| Borrows within reasonable limits? | Neutral |
| Stock is undervalued? | Fail |
| Have investors caught on? | Neutral |
| Has support of institutional investors? | Fail |
| Has sufficient liquidity? | Pass |
Fujifilm and Dr. Reddy's Call Off Joint Venture for Generic Drugs in Japan
Business Wire - Monday 06/03/2013 3:44 AM ET
| RDY | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | -- | |
| Net Income Growth (1yr) | -- | |
| Total Debt/Equity | -- | |
| LT Debt/Equity | -- | |
| Earnings Yield | -- | |
| Price/Sales | -- |
| Company | Last | Change |
|---|---|---|
| Pharmacyclics Inc | 88.26 | +1.23% |
| Endo Health Solutions Inc | 38.82 | -1.22% |
| Cubist Pharmaceuticals Inc | 51.13 | +2.32% |
| United Therapeutics Corp | 65.67 | +1.41% |
| Taro Pharmaceutical Industries Ltd | 57.58 | -0.81% |
Data is delayed by at least 15 min.